Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum β-lactamases from multiple regional Canadian hospitals

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 24, Issue 3, 2013, Pages

  Beuk, Carlee ^a   Hill, Christian ^c   Whitehead, Sue ^b   Blondel Hill, Edith ^c   Wagner, Ken ^a   Cheeptham, Naowarat ^a  

^a THOMPSON RIVERS UNIVERSITY   (Canada)

^b ROYAL INLAND HOSPITAL   (Canada)

^c KELOWNA GENERAL HOSPITAL   (Canada)

Author keywords

Antibiotic resistance; Canada; ESBL producing Enterobacteriaceae; Fosfomycin; Regional hospitals; Southern Interior BC; Tigecycline

Indexed keywords

FOSFOMYCIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BODY FLUID; CONTROLLED STUDY; DISK DIFFUSION; EPSILOMETER TEST; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GALLBLADDER; NONHUMAN; URINALYSIS; WOUND;

EID: 84888188828     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/645018     Document Type: Article

References (12)

1. Paterson DL. Resistance in Gram-negative bacteria. Am J Infect Control 2006;34:S20-S28.
2. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56: 52-9.
3. de Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-β-lactamaseproducing Escherichia coli and Klebsiella pneumoniae: Comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006;50:368.
4. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006;43: 518-24.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 2009 Vol. 31 No. 1
6. BioMerieux SA. 2010. Summary of Etest® Performance, Interpretive Criteria and Quality Control Ranges. 16029 A - 2010/06.
7. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagnostic Microbiol Infect Dis 2005;52: 209-13.
8. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatments of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis 2010;10: 43-50.
9. Shanthi M, Sekar U. Invitro activity of tigecycline against Gram positive and Gram negative isolates in a tertiary care hospital. J Clin Diagnos Res 2011;5: 1559-63.
10. Morosini M, Garcia-Castillo M, Coque TM, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006;50: 2695-9.
11. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006;50: 3479-84.
12. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East and Africa Between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Therapeutics 2012;34: 124-37.